Publicaciones (29) Publicaciones de GUILLERMO MAESTRO DE LA CALLE

2023

  1. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

    Kidney International Reports, Vol. 8, Núm. 8, pp. 1514-1530

  2. Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

    International Journal of Epidemiology, Vol. 52, Núm. 2, pp. 355-376

  3. Characteristics of clinical trials of influenza and respiratory syncytial virus registered in ClinicalTrials.gov between 2014 and 2021

    Frontiers in Public Health, Vol. 11

  4. Impact of days elapsed from the onset of symptoms to hospitalization in COVID-19 in-hospital mortality: Time matters

    Revista Clinica Espanola, Vol. 223, Núm. 5, pp. 281-297

  5. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

  6. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 5

2022

  1. A predictive score at admission for respiratory failure among hospitalized patients with confirmed 2019 Coronavirus Disease: a simple tool for a complex problem

    Internal and Emergency Medicine, Vol. 17, Núm. 2, pp. 515-524

  2. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

    International Journal of Infectious Diseases, Vol. 117, pp. 56-64

  3. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 761-775

  4. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  5. Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors

    Pathogens, Vol. 11, Núm. 10

  6. Rapid diagnosis of pulmonary tuberculosis using Xpert MTB/RIF assay in gastric aspirate samples from adult patients with sputum-absent disease: A first-step alternative to bronchoscopy?

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 40, Núm. 7, pp. 409-410

  7. The importance of association of comorbidities on COVID-19 outcomes: a machine learning approach

    Current Medical Research and Opinion, Vol. 38, Núm. 4, pp. 501-510

2021

  1. Beta-2-Glycoprotein-I Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019

    ACR Open Rheumatology, Vol. 3, Núm. 4, pp. 267-276

  2. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study

    International Journal of Infectious Diseases, Vol. 105, pp. 487-494

  3. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

    International Journal of Infectious Diseases, Vol. 105, pp. 319-325

  4. Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  5. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  6. Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 6, pp. 1209-1216

  7. Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination

    PLoS Pathogens, Vol. 17, Núm. 12